SGCG and metabolic disease: Several MAM modulators are under preclinical studies for cancer and metabolic disorders that target MAM structures by disrupting the ER‐mitochondria tethering proteins, the MAM‐resident proteins at their translational level, or the upstream signaling molecules, such as S1R.25